News | Vascular Closure Devices | February 21, 2018

Cardiva Medical Announces $41 Million for AMBULATE Vascular Closure Device Trial

New vascular closure device for multi-access mid-bore vein procedures, specifically cardiac ablation, aims to reduce time to ambulation and improve the patient experience

Cardiva Medical Announces $41 Million for AMBULATE Vascular Closure Device Trial

February 21, 2018 – Vascular closure device provider Cardiva Medical announced that the company has closed on $11 million in additional financing – bringing total equity and debt financing in the current round to $41 million. The additional financing exceeds previous commitments for this round and includes returning equity and debt investors – including PTV Healthcare Capital, Canepa Healthcare, and affiliates of Luther King Capital Management.

Funds will be used to continue U.S. commercial expansion of the Vascade Vascular Closure System and to fund the AMBULATE clinical trial, an investigational device exemption (IDE) study of Cardiva’s investigational closure system for mid-bore veins (defined as 6-12 French inner diameter access sheaths) used in cardiac ablation and other transcatheter procedures.

Cardiac ablation procedures are performed by specialized electrophysiologists with the goal of relieving symptoms and reducing the risk of stroke for patients with atrial fibrillation, a rhythm abnormality affecting up to 6.1 million Americans. Upon completion of these procedures, multiple access sites remain from the catheters inserted via the femoral veins in the groin. Today these sites are closed by application of manual compression and the patient is confined to bed for up to six hours prior to ambulation to protect the vascular puncture sites.

The AMBULATE Trial is a prospective, multi-center, randomized, controlled study enrolling 204 patients at sites across the United States. Patients are randomized to vessel closure with the Cardiva Medical system versus standard manual compression. The goal of the AMBULATE Trial is to significantly reduce the time to ambulation for patients following these complex electrophysiology procedures.

Principal investigators include Andrea Natale, M.D., executive medical director, Texas Cardiac Arrhythmia Institute; Mintu Turakhia, M.D., MAS, associate professor, Stanford University School of Medicine; and Steve Compton, M.D., of the Alaska Heart and Vascular Institute.

There are over 6 million interventional arterial procedures a year in the United States alone, and bleeding at the access site remains the No. 1 source of complications for these patients. The Vascade Vascular Closure System is the only closure system, according to Cardiva, to demonstrate a statistically significant reduction in access site complications in a prospective, randomized controlled clinical trial called RESPECT. The RESPECT study included 420 patients at 20 U.S. centers, comparing Vascade to manual compression for femoral arterial closure.

Vascade is commercially available in the United States, where it has been approved by the U.S. Food and Drug Administration (FDA), and has received CE Mark.

For more information: www.cardivamedical.com

 

Related Content

TCT cancels in-person meeting and goes virtual due to COVID-19
News | Cath Lab | May 27, 2020
May 27, 2020 — To ensure the health and safety of all attendees due to the ongoing COVID-19 (SARS-CoV-2) pandemic, th
Patients undergoing cardiac catheterization are traditionally instructed to follow nothing by mouth, or nil per os (NPO), as there are no current standardized fasting protocols, but the CHOWNOW study found patients do not need to fast and will have similar outcomes. #SCAI2020
Feature | Cath Lab | May 18, 2020
May 18, 2020 – Patients undergoing cardiac catheterization are traditionally instructed to follow nothing by mouth, o
Ehtisham Mahmud, M.D., FSCAI, president of the Society for Cardiovascular Angiography and Interventions (SCAI) and chief, Division of Cardiovascular Medicine at UC San Diego Medical Center,
Podcast | Cath Lab | May 13, 2020
This podcast is an interview with Ehtisham Mahmud, M.D., FSCAI, president of the Society for Cardiovascular Angiograp
Nuance Communications Inc. introduced Nuance Cardiovascular CAPD, a new computer-assisted physician documentation (CAPD) solution designed to help cardiologists improve the quality of complex documentation and the accuracy of reimbursement for cardiac catheterization procedures. The Nuance Cardiovascular CAPD solution is available through a partnership with ZHealth for this solution, which is based on patented algorithms built with ZHealth’s interventional documentation and coding expertise.
News | Cath Lab | January 31, 2020
January 29, 2020 – Nuance Communications Inc.
Videos | Cath Lab | January 09, 2020
Haval Chweich, M.D., medical director of the cardiac critical care unit (CCU) at Tufts Medical Center, and assistant...
People watch the live presentation of the five-year EXCEL Trial data by Gregg Stone, M.D., in the Abbott booth at TCT 2019. Abbott makes the Xience stent used in the trial, which compared equally with long-term CABG surgical outcomes.  In early December 2019, leaders of the European Association for Cardiothoracic Surgery (EACTS) withdrew their support for European practice guidelines that endorse the use of coronary stents in many patients with left main coronary artery disease.

People watch the live presentation of the five-year EXCEL Trial data by Gregg Stone, M.D., in the Abbott booth at TCT 2019. Abbott makes the Xience stent used in the trial, which compared equally with long-term CABG surgical outcomes.

News | Cath Lab | January 02, 2020 | Dave Fornell, Editor
January 2, 2020 — In early December 2019, leaders of the European As...